Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cells

Biochemical Pharmacology

Volumn 58, Issue 8, 1999, Pages 1247-1257

  Khélifa, Tayeb ^a   Beck, William T ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apoptosis; c Jun; Caspases; Dioxopiperazine; JNK1; Topoisomerase II

Indexed keywords

CASPASE; DNA FRAGMENT; DNA TOPOISOMERASE (ATP HYDROLYSING); PIPERAZINEDIONE; RAZOXANE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CAENORHABDITIS ELEGANS; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DENSITOMETRY; ENZYME INHIBITION; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPARAGINE; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CASPASES; CELL DIVISION; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; ENZYME INHIBITORS; GENE EXPRESSION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-JUN; RAZOXANE; SIGNAL TRANSDUCTION; TENIPOSIDE; TUMOR CELLS, CULTURED;

EID: 0344117807     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00213-0     Document Type: Article

References (52)

1. Nitiss J.L., Beck W.T. Anti-topoisomerase drug action and resistance. Eur J Cancer. 42A:1996;958-966.
2. Jensen P.B., Sorensen B.S., Sehested M., Demant E.J., Kjeldsen E., Friche E., Hansen H.H. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA cleavage and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol. 45:1993;2025-2035.
3. Tanabe K., Ikegami Y., Ishida R., Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res. 51:1991;4903-4908.
4. Ishida R., Miki T., Narita T., Yui R., Sato M., Utsumi K.R., Tanabe K., Andoh T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors . Cancer Res. 51:1991;4909-4916.
5. Drake F.H., Hofmann G.A., Mong S.M., Bartus J.O., Hertzberg R.P., Johnson R.K., Mattern M.R., Mirabelli C.K. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res. 49:1989;2578-2583.
6. Roca J., Ishida R., Berger J.M., Andoh T., Wang J.C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA. 91:1994;1781-1785.
7. Gorbsky G.J. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane). Cancer Res. 54:1994;1042-1048.
8. Onishi Y., Azuma Y., Kizaki H. Bis(2,6-dioxopiperazine) derivatives, topoisomerase II inhibitors which do not form a DNA cleavable complex, induce thymocyte apoptosis. Biochem Mol Biol Int. 32:1994;115-122.
9. Kizaki H., Onishi Y. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells. Adv Enzyme Regul. 37:1997;403-423.
10. Wyllie A.H. Apoptosis An overview . Br Med Bull. 53:1997;451-465.
11. Kostura M.J., Tocci M.J., Limjuco G., Chin J., Cameron P., Hillman A.G., Chartrain N.A., Schmidt J.A. Identification of a monocyte specific pre-interleukin 1β convertase activity. Proc Natl Acad Sci USA. 86:1989;5227-5231.
12. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J.-Y. Human ICE/CED-3 protease nomenclature. Cell. 87:1996;171.
13. Thornberry N.A., Molineaux S.M. Interleukin-1β converting enzyme A novel cysteine protease required for IL-1β production and implicated in programmed cell death . Protein Sci. 4:1995;3-12.
14. Thornberry N.A. The caspase family of cysteine proteases. Br Med Bull. 53:1997;478-490.
15. Davis R.J. MAP kinases New JNK expands the group . Trends Biochem Sci. 19:1994;470-473.
16. Sanchez I., Hughes R.T., Mayer B.J., Yee K., Woodgett J.R., Avruch J., Kyriakis J.M., Zon L.I. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature. 372:1994;794-798.
17. Derijard B., Raingeaud J., Barrett T., Wu I.-H., Han J., Ulevitch R.J., Davis R.J. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science. 267:1995;682-685.
18. Lin A., Minden A., Martinetto H., Claret F.-X., Lange-Carter C., Mercurio F., Johnson G.L., Karin M. Identification of a dual specificity kinase that activates Jun kinases and p38-Mpk2. Science. 268:1995;286-290.
19. Adler V., Franklin C.C., Kraft A.S. Phorbol esters stimulate the phosphorylation of c-Jun but not v-Jun Regulation by the N-terminal δ domain . Proc Natl Acad Sci USA. 89:1992;5341-5345.
20. Hibi M., Lin A., Smeal T., Minden A., Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 7:1993;2135-2148.
21. Pulverer B.J., Kyriakis J.M., Avruch J., Nikolakaki E., Woodgett J.R. Phosphorylation of c-Jun mediated by MAP kinases. Nature. 353:1991;670-674.
22. Smeal T., Binetruy B., Mercola D.A., Birrer M., Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature. 354:1991;494-496.
23. Franklin C.C., Sanchez V., Wagner F., Woodgett J.R., Kraft A.S. Phorbol ester-induced amino-terminal phosphorylation of human JUN but not JUNB regulates transcriptional activity. Proc Natl Acad Sci USA. 89:1992;7247-7251.
24. Gupta S., Campbell D., Derijard B., Davis R.J. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science. 267:1995;389-393.
25. Livingstone C., Patel G., Jones N. ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO J. 14:1994;1785-1797.
26. Whitmarsh A.J., Shore P., Sharrocks A.D., Davis R.J. Integration of MAP kinase signal transduction pathways at the serum response element. Science. 269:1995;403-407.
27. Hu M.C., Qiu W.R., Wang Y.P. JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene. 15:1997;2277-2287.
28. Sakata N., Patel H.R., Terada N., Aruffo A., Johnson G.L., Gelfand E.W. Selective activation of c-jun kinase mitogen-activated protein kinase by CD40 on human B cells. J Biol Chem. 270:1995;30823-30828.
29. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1995;1326-1331.
30. Liu Z.-G., Hsu H., Goeddel D.V., Karin M. Dissection of TNF receptor 1 effector functions JNK activation is not linked to apoptosis while NF-κB activation prevents cell death . Cell. 87:1996;565-576.
31. Goillot E., Raingeaud A., Ranger R.I., Tepper R.J., Davis E., Harlow T., Sanchez I. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci USA. 94:1997;3302-3307.
32. 2-terminal kinase and induction of apoptosis after detachment of epithelial cells. J Cell Biol. 139:1997;1017-1023.
33. Nishima H., Fischer K.D., Radvanyi L., Shahinian A., Hakem R., Rubie A.E., Bernstein A., Mak T.W., Woodgett J.R., Penninger J.M. Stress-signaling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3. Nature. 385:1997;350-353.
34. Yang X., Khosravi-Far R., Chang H.Y., Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 89:1997;1067-1076.
35. Nemoto S., Sheng Z., Lin A. Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy. Mol Cell Biol. 18:1998;3518-3526.
36. Danks M.K., Yalowich J., Beck W.T. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 47:1987;1297-1301.
37. Danks M.K., Schmidt C.A., Cirtain M.C., Suttle D.P., Beck W.T. Altered catalytic activity and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry. 27:1988;8861-8869.
38. Kusumoto H., Rodgers Q.E., Boege F., Raimondi S.C., Beck W.T. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Cancer Res. 56:1996;2573-2583.
39. Khélifa T., Beck W.T. Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease. Mol Pharmacol. 55:1999;548-556.
40. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
41. Kim R., Beck W.T. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26. Cancer Res. 54:1994;4958-4966.
42. Kearse K.P., Hart G.W. Lymphocyte activation induces rapid changes in nuclear and cytoplasmic glycoproteins. Proc Natl Acad Sci USA. 88:1991;1701-1705.
43. Talanian R.V., Quinlan C., Trautz S., Hackett M.C., Mankovich J.A., Banach D., Ghayur T., Brady K.D., Wong W.W. Substrate specificities of caspase family proteases. J Biol Chem. 272:1997;9677-9682.
44. Fortune J.M., Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase II α by blocking DNA cleavage. J Biol Chem. 273:1998;17643-17650.
45. Chen M., Beck W.T. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Oncol Res. 7:1995;103-111.
46. Fattman C.L., Allan W.P., Hasinoff B.B., Yalowich J.C. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells. Biochem Pharmacol. 52:1996;635-642.
47. Wasserman R.A., Wang J.C. Mechanistic studies of amsacrine-resistant derivatives of DNA topoisomerase II. Implications in resistance to multiple antitumor drugs targeting the enzyme. J Biol Chem. 269:1994;20943-20951.
48. 1 aspartate-based peptide α-((2,6-dichlorobenzoyl)oxy)methyl ketones as potent time-dependent inhibitors of interleukin-1β-converting enzyme. J Med Chem. 37:1994;563-564.
49. Mashima T., Naito M., Kataoka S., Kawai H., Tsuruo T. Aspartate-based inhibitor of interleukin-1β-converting enzyme prevents antitumor agent-induced apoptosis in human myeloid leukemia U937 cells. Biochem Biophys Res Commun. 209:1995;907-915.
50. Martins L.M., Kottke T., Mesner P.W., Basi G.S., Sinha S., Frigon N. Jr, Tatar E., Tung J.S., Bryant K., Takahashi A., Svingen P.A., Madden B.J., McCormick D.J., Earnshaw W.C., Kaufmann S.H. Activation of multiple interleukin-1β converting enzyme homologues in cytosol and nuclei of HL-60 cells during etoposide-induced apoptosis. J Biol Chem. 272:1997;7421-7430.
51. 2-terminal kinase-mediated activation of interleukin-1β converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J Biol Chem. 272:1997;4631-4636.
52. Haga N., Naito M., Seimiya H., Tomida A., Dong J., Tsuruo T. 2-Deoxyglucose inhibits chemotherapeutic drug-induced apoptosis in human monocytic leukemia U937 cells with inhibition of c-Jun N-terminal kinase 1/stress-activated protein kinase activation. Int J Cancer. 76:1998;86-90.